Osteosclerosis is a rare complication of multiple myeloma with an estimated incidence of up to 3%.' In most cases, however, there are isolated sclerotic deposits or mixed sclerotic and lytic lesions23 rather than diffuse osteosclerosis. A review ofpublished data4 showed only one case of osteosclerosis in a patient with IgD myeloma, although it is unclear whether this was solitary or diffuse. We report a case of IgD myeloma associated with generalised osteosclerosis which resulted from excessive osteoblastic activity, and we postulate that this was caused by the presence of an osteoblast stimulating factor secreted by the myeloma cells.
Case report
A 40 year old man, who had been exposed to intermittent industrial radiation for the previous 11 years, was first seen in September 1984 with a short history of lethargy. On examination the spleen extended 3 cm below the costal margin. The myeloma is common and more than 50% ofcases have lymphadenopathy, hepatomegaly, or splenomegaly. Renal impairment is more common than in IgG or IgA myeloma and the prognosis seems to be worse. 4 In a review of myeloma associated with myelofibrosis, three of 11 cases had IgD myeloma6-an unexpectedly high proportion. Similarly, patients with osteosclerotic lesions tend to be younger and to have a higher incidence of hepatosplenomegaly than other patients with myeloma.2 The unusual clinical and pathological features shown in our case, such as young age, lymphadenopathy, splenomegaly, myelofibrosis and short survival, while atypical for myeloma in general, would not be unexpected in osteosclerotic IgD myeloma.
In the common lytic form of myeloma it is recognised that the bone changes result from secretion by the myeloma cells of osteoclast activating factor (OAF), a cytokine with osteoclast stimulating activity,7 recently identified as lymphotoxin.8 In contrast, the mechanisms by which osteosclerosis is produced in myeloma remain poorly defined. In some cases there may be extensive bone marrow collagen fibrosis accompanied by osteosclerosis9; here the picture closely resembles that of the chronic myeloproliferative disorders, and myeloid metaplasia may also be present.6 Initially in our case, however, a different pathological mechanism was suggested because there was only moderate reticulin fibrosis and the radiological appearances were of a diffuse increase in bone density, without the loss of demarcation of the corticomedullary junction seen in osteosclerosis secondary to myeloproliferative disease. 'Ì n the plasma cell dyscrasia referred to as the POEMS syndrome (the symptom complex comprising polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes") it has been suggested that the commonly associated osteosclerosis"' may arise as a result of a different process, such as osteoclast dysfunction, or production by the myeloma cells of a factor which promotes osteoblastic activity." Increased osteoblastic activity has also been thought to result from invasion of the periosteum by malignant plasma cells.'3 High calcitonin concentrations, possibly leading to inhibition of bone resorption, have been described previously in a patient with osteosclerotic myeloma'4; on the other, production of an osteoblast stimulating factor was postulated as the cause of accelerated bone formation leading to hypocalcaemia in a patient with acute myelomonocytic leukaemia.'5 In our case, which lacked the cardinal features of the POEMS syndrome, the bone biopsy specimen showed osteosclerosis manifest as excess bone deposition on existing bone surfaces, with apparent dissociation between osteoblastic and osteoclastic activity. The histomorphometric studies seem to indicate that the generalised osteosclerosis seen in this patient resulted from excessive osteoblastic activity, rather than decreased osteoclasis. Although it is impossible to prove that myeloma was responsible for the generalised osteosclerosis, the association in this case, in the absence of another cause, raises the possibility that a humoral osteoblast stimulating factor was produced by the myeloma cells. Were this to be the case, by causing generalised osteoblastic stimulation, it would act in a different way to OAF, which seems to activate local osteoclasts.7 Nevertheless, there seems to be an analogy between osteosclerotic and typical myeloma as diffuse bone disturbance, whether osteosclerotic or osteopenic, can occur on its own in both types, although discrete lesions are more common.
